Dupilumab
R668-AD-1526
Approved small_molecule completed
Quick answer
Dupilumab for Moderate-to-Severe Atopic Dermatitis is a Approved program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Moderate-to-Severe Atopic Dermatitis
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed